TY - JOUR
T1 - Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure
T2 - Deficiency of ANP
AU - Reginauld, Shawn H.
AU - Cannone, Valentina
AU - Iyer, Seethalakshmi
AU - Scott, Christopher
AU - Bailey, Kent
AU - Schaefer, Jacob
AU - Chen, Yang
AU - Sangaralingham, S. Jeson
AU - Burnett, John C.
N1 - Funding Information:
Supported by National Heart, Lung and Blood Institute grants R01 HL36634 and RO1 HL13688 to Dr. Burnett and by the Mayo Foundation. Dr. Burnett holds equity in a patent licensed to Zumbro Discovery; and is consultant to Novartis and Ironwood. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2019 American College of Cardiology Foundation
PY - 2019/10
Y1 - 2019/10
N2 - Objectives: This study investigated the differential regulation of circulating atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in patients with acute decompensated heart failure (ADHF) and tested the hypothesis that a relative deficiency of ANP exists in a subgroup of patients with ADHF. Background: The endocrine heart releases the cardiac hormones ANP and BNP, which play a key role in cardiovascular (CV), renal, and metabolic homeostasis. In heart failure (HF), both plasma ANP and BNP are increased as a compensatory homeostatic response to myocardial overload. Methods: ANP and BNP concentrations were measured in a small group of patients with ADHF (n = 112). To support this study's goal, a total of 129 healthy subjects were prospectively recruited to establish contemporary normal values for ANP and BNP. Plasma 3′,5′cyclic guanosine monophosphate (cGMP), ejection fraction (EF), and body mass index (BMI) were measured in these subjects. Results: In cases of ADHF, 74% of patients showed elevated ANP and BNP. Importantly, 26% of patients were characterized as having normal ANP (21% of this subgroup had normal ANP and elevated BNP). Cyclic GMP was lowest in the ADHF group with normal levels of ANP (p < 0.001), whereas BMI and EF were inversely related to ANP levels (p = 0.003). Conclusions: Among a subgroup of patients hospitalized with ADHF, the presence of an ANP deficiency is consistent with a differential regulation of ANP and BNP and suggests the existence of a potentially compromised compensatory cardiac endocrine response. These findings have implications for the pathophysiology, diagnostics, and therapeutics of human HF.
AB - Objectives: This study investigated the differential regulation of circulating atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in patients with acute decompensated heart failure (ADHF) and tested the hypothesis that a relative deficiency of ANP exists in a subgroup of patients with ADHF. Background: The endocrine heart releases the cardiac hormones ANP and BNP, which play a key role in cardiovascular (CV), renal, and metabolic homeostasis. In heart failure (HF), both plasma ANP and BNP are increased as a compensatory homeostatic response to myocardial overload. Methods: ANP and BNP concentrations were measured in a small group of patients with ADHF (n = 112). To support this study's goal, a total of 129 healthy subjects were prospectively recruited to establish contemporary normal values for ANP and BNP. Plasma 3′,5′cyclic guanosine monophosphate (cGMP), ejection fraction (EF), and body mass index (BMI) were measured in these subjects. Results: In cases of ADHF, 74% of patients showed elevated ANP and BNP. Importantly, 26% of patients were characterized as having normal ANP (21% of this subgroup had normal ANP and elevated BNP). Cyclic GMP was lowest in the ADHF group with normal levels of ANP (p < 0.001), whereas BMI and EF were inversely related to ANP levels (p = 0.003). Conclusions: Among a subgroup of patients hospitalized with ADHF, the presence of an ANP deficiency is consistent with a differential regulation of ANP and BNP and suggests the existence of a potentially compromised compensatory cardiac endocrine response. These findings have implications for the pathophysiology, diagnostics, and therapeutics of human HF.
KW - acute decompensated heart failure
KW - atrial natriuretic peptide
KW - atrial natriuretic peptide deficiency
KW - natriuretic peptide
UR - http://www.scopus.com/inward/record.url?scp=85068647095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068647095&partnerID=8YFLogxK
U2 - 10.1016/j.jchf.2019.05.012
DO - 10.1016/j.jchf.2019.05.012
M3 - Article
C2 - 31521687
AN - SCOPUS:85068647095
SN - 2213-1779
VL - 7
SP - 891
EP - 898
JO - JACC: Heart Failure
JF - JACC: Heart Failure
IS - 10
ER -